VERA - CIK 0001831828
Vera Therapeutics, Inc. trades as VERA and has a market capitalization of $2.27 B, making it the #2012 largest US-listed company by market value. This page tracks Vera Therapeutics, Inc. through 447 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | Vera Therapeutics
The largest companies sharing Vera Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Vera Therapeutics, Inc. (VERA) has a market capitalization of $2.27 B as of 2026-06-10, ranking #2012 among US-listed companies.
In its latest fiscal year Vera Therapeutics, Inc. reported a net loss of $299.62M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.